News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,515 Results
Type
Article (7037)
Company Profile (9)
Press Release (177469)
Section
Business (52913)
Career Advice (80)
Deals (9212)
Drug Delivery (9)
Drug Development (30009)
Employer Resources (10)
FDA (4828)
Job Trends (4149)
News (95538)
Policy (7223)
Tag
Academia (552)
Alliances (8241)
Alzheimer's disease (523)
Approvals (4854)
Artificial intelligence (48)
Bankruptcy (69)
Best Places to Work (4072)
Breast cancer (112)
Cancer (768)
Cardiovascular disease (56)
Career advice (67)
CAR-T (31)
Cell therapy (119)
Clinical research (25450)
Collaboration (193)
Compensation (88)
COVID-19 (522)
C-suite (32)
Cystic fibrosis (36)
Data (820)
Diabetes (45)
Diagnostics (1577)
Earnings (33492)
Events (45112)
Executive appointments (143)
FDA (5138)
Funding (173)
Gene therapy (62)
GLP-1 (146)
Government (988)
Healthcare (5144)
Infectious disease (550)
Inflammatory bowel disease (54)
IPO (5479)
Job creations (385)
Job search strategy (58)
Layoffs (53)
Legal (1280)
Liver cancer (31)
Lung cancer (135)
Lymphoma (55)
Manufacturing (54)
Medical device (3369)
Medtech (3369)
Mergers & acquisitions (3853)
Metabolic disorders (120)
Neuroscience (671)
NextGen Class of 2024 (1341)
Non-profit (943)
Northern California (783)
Obesity (61)
Parkinson's disease (54)
People (9861)
Phase I (6195)
Phase II (10698)
Phase III (10254)
Pipeline (254)
Postmarket research (1169)
Preclinical (2633)
Prostate cancer (37)
Radiopharmaceuticals (64)
Rare diseases (106)
Real estate (752)
Regulatory (5458)
Research institute (551)
Southern California (692)
Startups (551)
United States (6447)
Vaccines (136)
Date
Today (2)
Last 7 days (132)
Last 30 days (1158)
Last 365 days (13514)
2024 (13485)
2023 (13479)
2022 (15935)
2021 (16716)
2020 (15599)
2019 (12668)
2018 (9490)
2017 (8902)
2016 (8396)
2015 (10493)
2014 (7674)
2013 (5636)
2012 (6213)
2011 (6619)
2010 (5836)
Location
Africa (101)
Arizona (41)
Asia (8947)
Australia (1416)
California (1747)
Canada (513)
China (143)
Colorado (84)
Connecticut (102)
Delaware (59)
Europe (24362)
Florida (195)
Georgia (51)
Illinois (136)
Indiana (92)
Japan (52)
Maryland (222)
Massachusetts (1394)
Michigan (45)
Minnesota (98)
New Jersey (558)
New York (492)
North Carolina (244)
Northern California (783)
Ohio (46)
Pennsylvania (343)
South America (172)
Southern California (692)
Texas (231)
Utah (45)
Washington State (190)
184,515 Results for "janssen l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).
January 5, 2024
·
3 min read
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement
September 6, 2023
·
9 min read
Press Releases
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
September 26, 2024
·
5 min read
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Business
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
January 8, 2024
·
2 min read
BioCapital
AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China
AbelZeta Pharma, Inc. announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.
December 14, 2023
·
5 min read
Business
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.
June 5, 2024
·
4 min read
Business
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
Cidara Therapeutics, Inc. has announced that Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered to Cidara its Election to Proceed Notice for CD388 (JNJ-0953) which is being developed for the universal prevention of influenza A and B.
September 6, 2023
·
5 min read
Policy
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.
December 1, 2023
·
6 min read
Policy
IBM Addresses Data Incident for Janssen CarePath Database
IBM is notifying Janssen CarePath customers and users of an incident involving unauthorized access to personal information contained within a database used on the Janssen CarePath platform, a patient support platform that offers savings options and other patient support resources.
September 6, 2023
·
2 min read
1 of 18,452
Next